Introduction {#s1}
============

Synaptic plasticity is a fundamental property of neurons that underlies the activities of neuronal circuits and behaviors. Neurons have a remarkable capacity to adjust outputs in response to external cues. Depending upon context, those adjustments can be stabilizing or destabilizing to overall function. Hebbian forms of neuroplasticity are generally thought to promote destabilizing changes. A great deal is known about the molecular mechanisms underlying Hebbian paradigms of synaptic plasticity like Long-Term Potentiation (LTP, e.g. [@bib55]) -- and how Hebbian plasticity might underlie long-lasting processes like memory formation and consolidation ([@bib1]; [@bib81]). Less is understood about homeostatic forms of neuroplasticity, which work to stabilize synapse function and keep activity levels within an acceptable physiological range ([@bib19]; [@bib20]; [@bib21]; [@bib82]; [@bib98]). For homeostatic plasticity, it is generally thought that coordinated actions of neurons and their targets work to maintain a set point functional parameter.

Well-studied examples of homeostatic synaptic plasticity (HSP) include synaptic scaling ([@bib67]; [@bib97]; [@bib99]), and the maintenance of evoked excitation at neuromuscular junctions (NMJs) ([@bib17]; [@bib20]; [@bib30]; [@bib78]). For both, the time course of implementation has been of longstanding interest. Synaptic scaling was initially shown to be a slow, chronically executed process ([@bib67]; [@bib97]), but it is also possible for faster scaling mechanisms to be mobilized if multiple synaptic sites are concurrently inhibited ([@bib95]). For the NMJ, homeostatic signaling is triggered by short-term challenges to synapse function ([@bib28]; [@bib106]), but it is also maintained for extended developmental time in the face of chronic challenges ([@bib17]; [@bib18]; [@bib22]; [@bib78]; [@bib80]).

The *Drosophila melanogaster* NMJ is an ideal model synapse for studying the basic question of how synapses work to counter destabilizing perturbations ([@bib30]). At this NMJ, reduced sensitivity to single vesicles of glutamate initiates a retrograde, muscle-to-nerve signaling cascade that induces increased neurotransmitter vesicle release, or quantal content (QC). As a result, the NMJ maintains a normal postsynaptic response level ([@bib28]; [@bib78]). Mechanistically, this increase in QC depends upon the successful execution of discrete presynaptic events, such as increases in neuronal Ca^2+^ influx and an increase in the size of the readily releasable pool (RRP) of synaptic vesicles ([@bib28]; [@bib63]; [@bib61]). The field has termed this compensatory signaling process as presynaptic homeostatic potentiation (PHP) ([@bib21]). Two factors that govern the expression of PHP are the nature of the NMJ synaptic challenge and the amount of time elapsed after presentation of the challenge. Acute pharmacological inhibition of postsynaptic glutamate receptors initiates a rapid induction of PHP that restores synaptic output in minutes ([@bib28]). By contrast, genetic lesions and other long-term reductions of NMJ sensitivity to neurotransmitter induce PHP in a way that is sustained throughout life ([@bib9]; [@bib18]; [@bib22]; [@bib73]; [@bib78]).

We previously identified the *Plc21C* gene as a factor needed for PHP ([@bib9]). *Plc21C* encodes a *Drosophila* Phospholipase Cβ (PLCβ) homolog known to be neuronally expressed ([@bib89]) -- but recent ribosomal profiling data also indicates possible muscle expression of *Plc21C* ([@bib15]). In canonical signaling pathways, once PLCβ is activated by Gαq, it cleaves the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP~2~) into diacylglycerol (DAG) and inositol triphosphate (IP~3~). DAG can affect synaptic function by activating Protein Kinase C (PKC), while IP~3~ binds its receptor (IP~3~R) to trigger release of calcium from intracellular stores ([@bib47]; [@bib79]; [@bib96]). It is not understood which aspects of this signaling machinery are mobilized during PHP. Potential downstream consequences of PLCβ activity at the NMJ include phosphorylation of neuronal proteins, modulation of ion channel activity, and changes in localization of neurotransmission machinery ([@bib16]; [@bib37]; [@bib44]; [@bib77]; [@bib84]; [@bib111]).

For this study, we scrutinized PLCβ-directed signaling further. We tested whether PLCβ-directed signaling was required solely for the maintenance of PHP or if it could also be required for induction. In addition to PLCβ, we identified the IP~3~ Receptor (*Drosophila* Itpr, herein IP~3~R) and Ryanodine receptor (*Drosophila* RyR) as being part of the same signaling process. We found that neither PLCβ, nor IP~3~R, nor RyR are required for the rapid induction of PHP. Additionally, we found that the rapid induction of PHP is still possible in synapses already sustaining PHP. Surprisingly, we found that NMJs are capable of rapidly inducing PHP -- even when the sustained expression of PHP is already blocked by impairments in PLCβ, IP~3~R, or RyR signaling. Taken together, our data show that the induction and maintenance of PHP are separable. Even though there is compelling evidence that parts of the induction and maintenance signaling mechanisms overlap ([@bib34]), it is also true that acute PHP is possible in scenarios where long-term PHP is not.

Results {#s2}
=======

PLCβ loss uncouples the short-term induction of homeostatic plasticity from its long-term maintenance {#s2-1}
-----------------------------------------------------------------------------------------------------

Previously, we demonstrated that loss of function of *Plc21C*, a *Drosophila melanogaster* PLCβ gene, could dampen or eliminate the long-term maintenance of PHP ([@bib9]). We repeated some of those experiments. We used a fruit fly line containing both neuron- and muscle-GAL4 drivers as well as a *UAS-GluRIII\[RNAi\]* transgenic construct to provide a chronic homeostatic challenge to reduce quantal size ([@bib9]). *Pre-+Post* Gal4\>\>*UAS-GluRIII\[RNAi\]* NMJs have decreased quantal size (mEPSP, [Figure 1A](#fig1){ref-type="fig"}) and an offsetting, homeostatic increase in quantal content (QC, [Figure 1C](#fig1){ref-type="fig"}). This increase in release keeps excitatory postsynaptic potentials (EPSPs) at control levels ([Figure 1B](#fig1){ref-type="fig"}). By contrast, concurrent knockdown of *GluRIII* and *Plc21C* gene functions by RNAi (*Pre-+Post* Gal4\>\>*UAS-GluRIII\[RNAi\]+Plc21C\[RNAi\]*) leaves this form of homeostatic potentiation only partly intact ([Figure 1A--C](#fig1){ref-type="fig"}). There is a small QC increase compared to baseline ([Figure 1C](#fig1){ref-type="fig"}), but this QC increase is blunted compared to the homeostatic challenge, resulting in evoked potentials that are smaller than controls ([Figure 1B and D](#fig1){ref-type="fig"}). These data are consistent with the prior results ([@bib9]) ([Supplementary file 1](#supp1){ref-type="supplementary-material"} for summary [Figure 1](#fig1){ref-type="fig"} data) ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"} for raw data).

![Maintenance of presynaptic homeostatic potentiation requires PLCβ, but induction does not.\
(**A**) *GluRIII* knockdown induces a significant decrease in quantal size for both driver control and *Plc21C* knockdown genetic backgrounds. (**B**) EPSP amplitudes are maintained with *GluRIII* knockdown alone but dampened with concurrent *GluRIII* and *Plc21C* knockdown. (**C**) There is significant PHP (Presynaptic Homeostatic Potentiation, measured as an increase in quantal content) in response to *GluRIII* knockdown. (**D**) Representative electrophysiological traces of EPSPs (above) and mEPSPs (below). The evoked events show full PHP in the *GluRIII* RNAi knock down background and partial PHP with concurrent *Plc21C* knock down. (**E**) 10-min incubation with 20 μM PhTox diminishes quantal size for all conditions. (**F**) EPSP amplitudes after acute PhTox incubation are maintained at or near normal levels. (**G**) The data in (**F**) are because PHP is rapidly induced in wild-type and *Plc21C* RNAi NMJs after PhTox incubation. (**H**) Representative electrophysiological traces show fully intact PHP induction. (**I**) With dual PHP maintenance (GluRIII knockdown) and induction (PhTox application), quantal size is further decreased. (**J**) EPSP amplitudes after dual maintenance and induction. (**K**) Quantal is content further increased in by PhTox treatment in *GluRIII* RNAi synapses compared to untreated synapses; this expression of PHP does not require full PLCβ function. (**L**) Representative electrophysiological traces illustrate that even though PHP maintenance is impaired with PLCβ knockdown, PHP induction is not impaired. Violin plots have horizontal lines signifying the 0^th^, 25^th^, 50^th^, 75^th^, and 100^th^ percentiles of the data distribution; the distribution itself is delineated by the shapes of the plots. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 by Student's T-Test versus non-challenged genetic control or by one-way ANOVA with a Bonferroni post-hoc test in the case of comparing degree of compensation with *GluRIII* RNAi and *Plc21C* RNAi + *GluRIII* RNAi. Scale bars for all traces are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.003Figure 1---source data 1.Raw electrophysiology data for [Figure 1](#fig1){ref-type="fig"}.Values include EPSP amplitude in mV, resting membrane potential (RMP) in mV, mEPSP amplitude in mV, mEPSP frequency (Hz), quantal content, and quantal content corrected for non-linear summation (NLS).](elife-39643-fig1){#fig1}

The *GluRIII* RNAi knock down manipulation in muscle is a days-long, chronic homeostatic challenge to the maintenance of NMJ function ([@bib9]). We tested if *Plc21C* gene knock down blocks or impairs the acute induction of PHP. For acute induction, we applied 20 μM of the glutamate receptor antagonist Philanthotoxin-433 (PhTox) to both wild-type and to *Pre-+Post* Gal4\>\>*Plc21C\[RNAi\]* knock down NMJs. PhTox application decreased quantal size for both conditions ([Figure 1E](#fig1){ref-type="fig"}) ([@bib28]). For both conditions, evoked potentials remained largely steady compared to non-PhTox controls ([Figure 1F and H](#fig1){ref-type="fig"}) because there was a significant, compensatory increase in quantal content ([Figure 1G](#fig1){ref-type="fig"}). Thus, partial loss of *Plc21C* gene function is not a sufficient condition to block the rapid induction of PHP.

The induction of PHP is possible, even when PHP maintenance is impaired {#s2-2}
-----------------------------------------------------------------------

We used *Plc21C* loss and PhTox to test whether the capacity to maintain PHP for extended developmental time is required for rapid PHP induction. The most common modes of assessing PHP at the *Drosophila* NMJ are a lifelong, genetic *GluRIIA^SP16^* null mutation for PHP maintenance ([@bib78]) and acute PhTox application for PHP induction ([@bib28]). For both cases, mEPSP amplitudes are decreased and QC is increased helping to maintain evoked potentials at (or nearly at) normal levels. PhTox targets the function of GluRIIA-containing receptors; thus, adding PhTox to a *GluRIIA^SP16^* null background does not further decrease quantal size ([@bib28]). This fact presents a difficulty in using PhTox and *GluRIIA^SP16^* together to test whether additional PHP can be acutely induced in a chronic glutamate receptor loss genetic condition already sustaining PHP. We reasoned that by applying PhTox to *UAS-GluRIII\[RNAi\]* knock down synapses, we could circumvent this limitation. Partial loss of the essential subunit-encoding *GluRIII* gene leaves some GluRIIA-containing receptors intact ([@bib9]). In turn, those GluRIIA-containing receptors could be subject to the secondary PhTox challenge.

We applied PhTox to *UAS-GluRIII\[RNAi\]* synapses, and we observed a further decrease in quantal amplitude -- significantly below mEPSP size recorded for *UAS-GluRIII\[RNAi\]* alone ([Figure 1I](#fig1){ref-type="fig"}). Evoked potentials were only slightly lower than the non-PhTox levels ([Figure 1J,L](#fig1){ref-type="fig"}) because there was a robust increase in QC ([Figure 1K](#fig1){ref-type="fig"}). This result indicated that a rapid induction of PHP was possible at a synapse already undergoing a sustained maintenance of PHP.

We next tested whether compromised ability to sustain PHP throughout life would also preclude acute induction of PHP. PhTox applied to NMJs simultaneously expressing both *UAS-GluRIII\[RNAi\]* and *Plc21C\[RNAi\]* constructs induced a significant decrease in mEPSP amplitude relative to non-PhTox-treated control synapses ([Figure 1I](#fig1){ref-type="fig"}). Yet we also observed a significant increase in QC (i.e. PHP induction) ([Figure 1K](#fig1){ref-type="fig"}), which kept evoked NMJ potentials similar to their non-PhTox levels ([Figure 1J,L](#fig1){ref-type="fig"}). Collectively, these data suggest that acute PHP induction does not require intact PHP maintenance and that PLCβ plays a maintenance role.

IP~3~ function is required for the maintenance of PHP but not its induction {#s2-3}
---------------------------------------------------------------------------

We sought to identify potential PLCβ signaling effectors that could mediate the long-term maintenance of PHP. We screened targets by electrophysiology. Based on canonical signaling functions of PLCβ, we conducted a directed screen, targeting molecules such as PKC, CaMKII, Unc-13, related signaling molecules, as well several potential G-protein-coupled receptors (GPCRs). Additionally, we tested molecules implicated in intracellular calcium signaling, intracellular ion channel function, and synaptic ion channel function.

We used a screening paradigm designed to find factors needed for the maintenance of PHP: combining pre- and postsynaptic GAL4 expression with *UAS-GluRIII\[RNAi\]* with a tested genetic manipulation ([@bib9]). We targeted factors for this screen using either *UAS-gene* misexpression or *UAS-gene\[RNAi\]* constructs. We also used loss-of-function mutations. For an additional screening condition for some mutations, we constructed double mutant lines with a *GluRIIA^SP16^* null deletion allele ([@bib78]). For any test, we analyzed two conditions: a baseline neurotransmission condition (e.g. GAL4 +genetic manipulation alone) and a homeostatically challenged condition (e.g. GAL4 +genetic manipulation+*UAS-GluRIII\[RNAi\]*). Any homeostatically challenged condition that failed to increase QC over its own baseline condition was designated as a potential positive.

We examined 28 distinct genetic manipulations (comprising 23 distinct genes), including controls ([Figure 2A](#fig2){ref-type="fig"}) ([Supplementary file 2](#supp2){ref-type="supplementary-material"} for summary [Figure 2](#fig2){ref-type="fig"} data) ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"} for raw data). We plotted the relative QC values for the screen as '% baseline' ([Figure 2A](#fig2){ref-type="fig"}), indicating how much of a QC change the *UAS-GluRIII\[RNAi\]* challenge yielded. We set a cutoff for a 'screen positive' as a QC smaller than one standard deviation below the expected QC given the *UAS-GluRIII\[RNAi\]* homeostatic challenge ([Figure 2A](#fig2){ref-type="fig"}, red dashed line).

![IP~3~ sequestration blocks PHP maintenance but not PHP induction.\
(**A**) Screen data, plotting baseline quantal content (QC, *x*-axis, genetic manipulation alone) versus QC of the homeostatically challenged condition (*y*-axis, *GluRIII RNAi* or *GluRIIA* mutant). Blue = *GluRIIA* alone. Green = *GluRIII* RNAi alone. Red = *GluRIII RNAi+UAS-IP~3~-sponge.* Dotted line = one standard deviation below the mean QC of *GluRIII* RNAi. (**B**) Representative electrophysiological traces (EPSPs above; mEPSPs below), demonstrating diminished evoked potentials in the *GluRIII RNAi +UAS-IP~3~-sponge* (presynaptic +postsynaptic expression) condition. (**C**) *GluRIII* knockdown induces a significant decrease in quantal size for all genetic backgrounds. (**D**) EPSP amplitudes are maintained with *GluRIII* knockdown alone but significantly diminished with concurrent *GluRIII* knockdown and expression of either *UAS-IP~3~-sponge line*. (**E**) By quantal content, sustained PHP expression is abolished when *UAS-IP~3~-sponge* is expressed using concurrent pre- and postsynaptic GAL4 drivers. (**F**) 10-min incubation with 20 μM PhTox diminishes quantal size for all conditions. (**G**) EPSP amplitudes after acute PhTox incubation are maintained at or near normal levels for all conditions. (**H**) Failure to sustain PHP following IP~3~ sequestration does not preclude its rapid induction. The data in (**G**) are because PhTox treatment results in a compensatory increase in QC for conditions shown. (**I**) Representative electrophysiological traces showing full homeostatic compensation with PhTox application (as in [@bib28]). (**J**) Representative traces of the experimental data in (**F--H**). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 by Student's T-Test versus non-challenged genetic control. Scale bars for all traces are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.005Figure 2---source data 1.Raw electrophysiology data for *UAS-IP~3~-sponge* experiements in [Figure 2](#fig2){ref-type="fig"}.Values as in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-39643-fig2){#fig2}

Two genetic manipulations showed no statistically significant QC increase upon homeostatic challenge ([Figure 2A](#fig2){ref-type="fig"}, red). For both manipulations, the screened target molecule was inositol 1,4,5-triphosphate (IP~3~). IP~3~ is a second-messenger signaling molecule. We examined it because PLCβ cleaves the phospholipid PIP~2~ into soluble IP~3~ and membrane-bound diacylglycerol (DAG) during canonical signaling. We targeted cellular IP~3~ by expressing *UAS-IP~3~-sponge*, a transgene that expresses a peptide that binds and sequesters IP~3~ ([@bib100]). Concomitant pre-and postsynaptic expression of *UAS-IP~3~-sponge* transgenes completely blocked the long-term expression of PHP ([Figure 2B--E](#fig2){ref-type="fig"}). This resulted in significantly smaller EPSP amplitudes in the *UAS-GluRIII\[RNAi\]* PHP-challenge genetic background. ([Figure 2B,D](#fig2){ref-type="fig"}).

We used the full block of sustained PHP by *UAS-IP~3~-sponge* expression to re-test the relationship between the rapid induction of PHP and its long-term maintenance. First, we tested if *UAS-IP~3~-sponge* expression alone could block the rapid induction of PHP. Following PhTox treatment, synapses expressing *UAS-IP~3~-sponge* in pre- and postsynaptic tissues showed a significant decrease in mEPSP amplitude compared to non-PhTox controls ([Figure 2F](#fig2){ref-type="fig"}), and yet they had steady EPSP amplitudes ([Figure 2G](#fig2){ref-type="fig"}) because of a robust increase in QC ([Figure 2H](#fig2){ref-type="fig"}). This result indicated that *UAS-IP~3~-sponge* expression left the rapid induction mechanisms of PHP intact.

We next tested if the rapid induction of PHP was possible for third instar larval NMJs that had blocked PHP maintenance throughout life. To do this, we applied PhTox to NMJs expressing *UAS-IP~3~-sponge* in a *UAS-GluRIII\[RNAi\]* background. Even in this genetic background, we found that the rapid induction of PHP remained intact following PhTox treatment ([Figure 2F--H](#fig2){ref-type="fig"}). PhTox treatment resulted in a further decrease in mEPSP amplitude compared to non-PhTox-treated synapses expressing both *UAS-GluRIII\[RNAi\]* and *UAS-IP~3~-sponge* ([Figure 2F](#fig2){ref-type="fig"}), but there was an offsetting increase in QC ([Figure 2H](#fig2){ref-type="fig"}). The evoked event amplitudes were at the level of genetically identical, non-PhTox-treated synapses ([Figure 2G](#fig2){ref-type="fig"}), because of successful induction of PHP in a genetic background that was unable to sustain PHP throughout development.

IP~3~ sequestration does not impair synapse growth {#s2-4}
--------------------------------------------------

Chronic expression of the *UAS-IP~3~-sponge* transgene blocked the long-term expression of PHP. In principle, this result could be a secondary consequence of aberrant NMJ development. To check this possibility, we co-immunostained third instar larval *Drosophila* NMJs with anti-Synapsin (Syn, presynaptic vesicles), anti-Discs Large (Dlg, postsynaptic density), and anti-Horseradish Peroxidase (HRP, presynaptic membrane) antibodies. This allowed us to examine synaptic growth by counting NMJ boutons. We quantified bouton growth for synapse 6/7, muscle segments A2 and A3. We examined control conditions and conditions with blocked PHP maintenance due to *UAS-IP3-sponge* expression ([Figure 3A--E](#fig3){ref-type="fig"}). We observed no significant differences versus control in bouton number for any condition, for either segment A2 or A3 -- including the genetic background where we co-expressed *UAS-IP3-sponge* and *UAS-GluRIII\[RNAi\]* ([Figure 3F](#fig3){ref-type="fig"}). There were also no significant differences versus control in bouton number normalized per unit muscle area ([Figure 3G](#fig3){ref-type="fig"}) ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"} for raw bouton count and muscle size data). These data indicate that when IP~3~ is sequestered, synapse undergrowth is not causal for a PHP block.

![IP~3~ sequestration does not impair NMJ growth.\
(**A--E**) NMJs were co-stained with anti-DLG (red) and anti-Synapsin antibodies (green) to visualize synaptic boutons, with anti-HRP (blue) to visualize presynaptic membranes. Genotypes or conditions as indicated. All scale bars, 10 μm. (**F**) NMJ growth was assessed by bouton counting at abdominal segments A2 and A3, muscle 6/7, based on postsynaptic DLG staining and double checked for presynaptic Synapsin. No statistically significant differences in NMJ growth versus driver control were observed for any of the experimental conditions (p\>0.1 vs. control, regardless of segment). (**G**) Bouton counts were normalized per unit of muscle 6/7 area. No statistically significant differences versus control were observed (p\>0.2 vs. control, regardless of segment). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. For both F and G, data were compared for each segment individually using the Kruskal-Wallis ANOVA test followed by Dunn's multiple comparisons test.\
10.7554/eLife.39643.007Figure 3---source data 1.Raw synapse growth data for [Figure 3](#fig3){ref-type="fig"}.These measures include bouton counts, muscle area (µm^2^), and boutons per µm^2^.](elife-39643-fig3){#fig3}

Pharmacology targeting IP~3~ receptors uncouples the induction and maintenance of PHP {#s2-5}
-------------------------------------------------------------------------------------

We tested if the temporal requirements of PHP could be uncoupled by pharmacological disruption of *Drosophila* IP~3~ receptor function (Itpr in *Drosophila*). IP~3~Rs are localized to the endoplasmic reticulum (ER) and function to mediate calcium efflux from internal stores ([@bib3]; [@bib4]). ER is known to localize throughout neurons in *Drosophila*, including synaptic terminals ([@bib93]). Recent studies have implicated ER resident proteins in the execution of PHP ([@bib33]) or in baseline neurotransmission and synapse growth ([@bib49]) at the *Drosophila* NMJ. To target IP~3~Rs, we turned to two reagents known to impair function: Xestospongin C and 2-APB (2-Aminoethoxydiphenyl Borate) and applied those drugs to *GluRIIA* loss-of-function mutants.

Xestospongin C is a membrane-permeable drug that disrupts intracellular calcium release directly via non-competitive inhibition of IP~3~Rs ([@bib32]; [@bib109]). Xestospongin C has been previously shown to inhibit *Drosophila* IP~3~Rs ([@bib101]). There are caveats to its use; Xestospongin C may act indirectly by inhibiting SERCA, which could lead to depletion of intracellular calcium stores ([@bib12]). Moreover, Xestospongin C has been demonstrated to impair voltage-gated Ca^2+^ and K^+^ currents in guinea pig smooth muscle ([@bib72]). In principle, these latter activities on intact fly NMJ tissue could impact baseline neurotransmission parameters ([@bib2]; [@bib9]; [@bib45]; [@bib75]).

*GluRIIA^SP16^* null mutant NMJs have a marked decrease in quantal size ([Figure 4A](#fig4){ref-type="fig"}) ([@bib78]). This homozygous null condition does not perfectly maintain control EPSP amplitudes ([Figure 4B](#fig4){ref-type="fig"}) ([@bib9]; [@bib28]; [@bib29]; [@bib91]; [@bib113]). However, the null does induce a robust increase in QC, which signifies a long-term implementation of PHP ([Figure 4C](#fig4){ref-type="fig"}). *GluRIIA^SP16^* NMJ preparations acutely treated with 20 μM Xestospongin C (10 min) displayed an expected decrease in mEPSP amplitude compared to non-*GluRIIA^SP16^* controls ([Figure 4A](#fig4){ref-type="fig"}). However, these drug-treated NMJs failed to show an increase in QC ([Figure 4C](#fig4){ref-type="fig"}). This resulted in markedly decreased evoked amplitudes ([Figure 4B,G](#fig4){ref-type="fig"}). Thus, not only did 20 μM Xestospongin C induce a block of PHP maintenance, but it was capable of extinguishing this long-term maintenance process on a timescale of minutes.

Importantly, 20 μM Xestospongin C did not impair baseline neurotransmission in a wild-type background ([Figure 4B,G](#fig4){ref-type="fig"}); this suggests that 20 μM Xestospongin C does not impair the function of other important voltage-gated channels at the *Drosophila* NMJ. Finally, in the *GluRIIA* null background, neither a lower dose (5 μM Xestospongin C) nor vehicle application alone inhibited the expression of PHP ([Figure 4A--C](#fig4){ref-type="fig"}) ([Supplementary file 3](#supp3){ref-type="supplementary-material"} for summary [Figure 4](#fig4){ref-type="fig"} data) ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"} for raw data).

![Xestospongin C blocks PHP maintenance but not PHP induction.\
Xestospongin C acutely applied to NMJs to impair IP~3~R function. (**A**) The *GluRIIA^SP16^* deletion mutation diminishes quantal size for all experimental conditions. (**B**) EPSP amplitudes are somewhat impaired versus non-*GluRIIA* control in all cases but most severely impaired when *GluRIIA* deletion is combined with 20 µM Xestospongin C incubation. (**C**) By quantal content, sustained PHP expression is abolished with acute NMJ exposure to 20 µM Xestospongin C. (**D**) Acute incubation 20 μM PhTox diminishes quantal size for all conditions (PhTox +DMSO vehicle or PhTox +20 µM Xestospongin C). (**E**) EPSP amplitudes are normal or near normal for all conditions. (**F**) Rapid PHP induction by PhTox not blocked by 20 µM Xestospongin C. (**G**) Representative electrophysiological traces (EPSPs above; mEPSPs below) for 20 µM Xestospongin C (or control) conditions in (**A--F**). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 by Student's T-Test versus non-challenged genetic control. Scale bars for all traces are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.009Figure 4---source data 1.Raw electrophysiology data for [Figure 4](#fig4){ref-type="fig"}.Values as in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-39643-fig4){#fig4}

Next, we tested if acute application of 20 μM Xestospongin C could block the rapid induction of PHP. We applied 20 μM Xestospongin C to wild-type NMJs concurrently with 20 μM PhTox. Quantal size was markedly diminished compared to the non-PhTox control ([Figure 4D](#fig4){ref-type="fig"}; vehicle control dataset same as in 4A-C). Yet evoked amplitudes remained near control levels ([Figure 4E,G](#fig4){ref-type="fig"}) because the rapid induction of PHP was intact ([Figure 4F](#fig4){ref-type="fig"}).

We used 2-APB as a second reagent to target IP~3~Rs. 2-APB is a membrane-permeable drug that has variable effects. It is known to impair IP~3~R ([@bib26]; [@bib58]). There are also reports that 2-APB can impair targets such as Transient Receptor Potential (TRP) channels ([@bib8]; [@bib112]). If continuous IP~3~R function were required for the maintenance PHP at NMJs, we reasoned that acute application of 2-APB (as with Xestospongin C) should also extinguish this form of neuroplasticity.

We applied both 1 μM and 10 μM 2-APB to *GluRIIA^SP16^* null NMJs. Both drug concentrations resulted in a failure to increase QC compared to drug-treated wild-type controls; this resulted in small evoked events for the drug-treated *GluRIIA^SP16^* NMJs because PHP maintenance was blocked ([Figure 5A--C,G](#fig5){ref-type="fig"}) ([Supplementary file 4](#supp4){ref-type="supplementary-material"} for summary [Figure 5](#fig5){ref-type="fig"} data) ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"} for raw data). Next, we tested if 2-APB blocks the PhTox-induced rapid induction of PHP. We applied 1 μM 2-APB concurrently with 20 μM PhTox. Evoked potentials remained near the level of 2-APB-treated NMJs without PhTox ([Figure 5E,H](#fig5){ref-type="fig"}) because 1 μM 2-APB left the rapid induction of PHP intact ([Figure 5D--F](#fig5){ref-type="fig"}).

![2-APB blocks PHP maintenance but not PHP induction.\
2-APB acutely applied to NMJs to impair IP~3~R function. Wild-type and *GluRIIA* control data sets are replotted from [Figure 4](#fig4){ref-type="fig"} for visual comparison. (**A**) The *GluRIIA^SP16^* deletion mutation diminishes quantal size for all experimental conditions. (**B**) EPSP amplitudes are somewhat impaired versus non-*GluRIIA* control in all cases but severely impaired when *GluRIIA* deletion is combined with either 1 µM or 10 µM 2-APB incubation. (**C**) By quantal content, sustained PHP expression is abolished with acute NMJ exposure to 1 µM or 10 µM 2-APB. (**D**) Acute incubation 20 μM PhTox diminishes quantal size for all conditions (PhTox +DMSO vehicle or PhTox +1 µM 2-APB). (**E**) EPSP amplitudes are normal or near normal for all conditions. (**F**) Rapid PHP induction by PhTox not blocked by 1 µM 2-APB. (**G**) Representative electrophysiological traces (EPSPs above; mEPSPs below) for 10 µM 2-APB (or control) conditions in (**A-C**). (**H**) Representative electrophysiological traces for 1 µM 2-APB (or control) conditions in (**D-F**). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 by Student's T-Test versus non-challenged genetic control. Scale bars in (G) also apply to (H) and are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.011Figure 5---source data 1.Raw electrophysiology data for [Figure 5](#fig5){ref-type="fig"}.Values as in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-39643-fig5){#fig5}

We note that 2-APB potentiated baseline neurotransmission, seemingly in a dose-dependent way ([Figure 5B,G](#fig5){ref-type="fig"}). This potentiation likely means that 2-APB had off-target effects at the NMJ in addition to IP~3~Rs. We considered that 2-APB could exert effects though TRP channels, like Drosophila Inactive (Iav). Iav plays a role in NMJ neurotransmission and controls Ca^2+^ levels in motor neurons ([@bib110]). However, knock down of *iav* gene function by RNAi did not impair PHP in our screen ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), and the effects of 2-APB on baseline neurotransmission appear to be the opposite of those reported for strong *iav* loss of function ([@bib110]). Taken together, our pharmacological data show that with acute drug application of either Xestospongin C or 2-APB, it is acutely possible to erase a lifelong, *GluRIIA^SP16^*-induced long-term expression of PHP. Since this erasure is accomplished with known inhibitors of IP~3~R, our data are consistent with the hypothesis that the maintenance of PHP requires continuous IP~3~R function.

Pharmacology targeting ryanodine receptors uncouples the induction and maintenance of PHP {#s2-6}
-----------------------------------------------------------------------------------------

Ryanodine receptors (RyRs) also mediate release of calcium from ER stores ([@bib5]; [@bib90]). RyRs are localized to the ER in excitable tissues like neurons and muscle ([@bib87]; [@bib86]). Therefore, we tested whether RyRs are also required for the maintenance of PHP at the NMJ. We repeated the same types of experiments executed with the IP~3~R pharmacological blockade -- this time targeting *Drosophila* RyRs by utilizing Ryanodine ([@bib64]) and Dantrolene ([@bib101]; [@bib115]) at concentrations previously reported to block RyRs. We acquired similar results as with IP~3~R blockade. Acute application of either 100 μM Ryanodine or 10 μM Dantrolene to *GluRIIA* null preparations resulted in failure of PHP maintenance. QC did not increase for the homeostatically challenged condition (*GluRIIA* +drug) versus the unchallenged condition (wild-type +drug) ([Figure 6A--C](#fig6){ref-type="fig"}) ([Supplementary file 5](#supp5){ref-type="supplementary-material"} for summary [Figure 6](#fig6){ref-type="fig"} data) ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"} for raw data).

Next, we tested whether RyR inhibition could block the rapid induction of PHP. As was the case with IP~3~R inhibition, acute application of 10 μM Dantrolene to PhTox-treated NMJs did not disrupt the short-term induction of PHP ([Figure 6D--F](#fig6){ref-type="fig"}). We extended our analysis by re-examining the condition where we combined a long-term homeostatic challenge (*GluRIII\[RNAi\]*) with a short-term challenge (PhTox) to further decrease quantal size (as in [Figure 1I--L](#fig1){ref-type="fig"}). In this double-challenge condition, addition of 10 μM Dantrolene left the rapid induction portion of PHP intact ([Figure 6D--G](#fig6){ref-type="fig"}). Collectively, these experiments demonstrate that acute pharmacological perturbations targeting RyRs are capable of uncoupling the short-term induction and the long-term maintenance of PHP.

![The maintenance of PHP requires continuous RyR function, but PHP induction does not.\
Ryanodine or Dantrolene acutely applied to NMJs to impair RyR function. Wild-type and *GluRIIA* control data sets are replotted from [Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"} for visual comparison. (**A**) The *GluRIIA^SP16^* deletion mutation diminishes quantal size for all experimental conditions. (**B**) EPSP amplitudes are somewhat impaired versus non-*GluRIIA* control in all cases but most severely impaired when *GluRIIA* deletion is combined with 10 µM Dantrolene. (**C**) By quantal content, sustained PHP expression is abolished with acute NMJ exposure to 100 µM Ryanodine or 10 µM Dantrolene. (**D**) Acute incubation 20 μM PhTox diminishes quantal size for all conditions shown. (**E**) EPSP amplitudes remain near genetic control levels for all conditions with PhTox application. (**F**) Rapid PHP induction by PhTox is intact in the presence of 10 µM Dantrolene, even when *GluRIII* has been knocked down throughout life. (**G**) Representative electrophysiological traces for the conditions in (**D--F**). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. Statistical comparisons are by Student's T-Test vs. unchallenged controls. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Scale bars for all traces are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.013Figure 6---source data 1.Raw electrophysiology data for [Figure 6](#fig6){ref-type="fig"}.Values as in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-39643-fig6){#fig6}

Dual IP~3~ sequestration and RyR blockade are not additive {#s2-7}
----------------------------------------------------------

In some tissues, RyR is activated by IP~3~R-mediated Ca^2+^ release, in a signaling process termed Calcium-Induced Calcium Release (CICR) ([@bib5]). IP~3~Rs and RyRs have been placed together in CICR signaling processes in other systems, and our group has also identified overlapping functions of IP~3~R and RyR at the NMJ ([@bib10]). Thus, we tested if IP~3~ signaling and RyR functions might support the maintenance of PHP at the *Drosophila* NMJ via a shared process. The expectation for a shared process would be that a dual block of PHP (consisting of IP~3~ sequestration +RyR pharmacological blockade) would not depress evoked transmission or quantal content below either individual manipulation.

A chronic *GluRIII\[RNAi\]*-expression NMJ challenge is amenable both to pharmacology and dual-tissue *UAS-IP~3~-sponge* expression (*Pre-+Post* Gal4). In the *GluRIII\[RNAi\]* genetic background, both 10 μM Dantrolene application and *UAS-IP~3~-sponge* expression blocked the long-term maintenance of PHP ([Figure 7A--C](#fig7){ref-type="fig"}). This resulted in EPSPs that were blunted compared to *GluRIII\[RNAi\]*-alone controls ([Figure 7B,D](#fig7){ref-type="fig"}). When we combined Dantrolene application and *UAS-IP~3~-sponge* expression in the *GluRIII\[RNAi\]* background, the PHP impairment was indistinguishable from the impairment elicited by Dantrolene alone or *UAS-IP~3~-sponge* alone ([Figure 7A--D](#fig7){ref-type="fig"}) ([Supplementary file 6](#supp6){ref-type="supplementary-material"} for summary [Figure 7](#fig7){ref-type="fig"} data) ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"} for raw data). The data are consistent with a model in which IP~3~ sequestration and RyR blockade disrupt the long-term maintenance of PHP as part of a shared process, either via a single linear pathway or convergent pathways.

![There are no additive effects of genetic IP~3~ signaling inhibition and pharmacological RyR inhibition.\
(**A**) *GluRIII* knockdown diminishes quantal size for all experimental conditions. (**B**) When challenged with *GluRIII* knockdown, EPSP amplitudes are maintained for the GAL4 driver control background but impaired for all other experimental backgrounds. The dual manipulation of 10 µM Dantrolene +*UAS-IP~3~-sponge* is indistinguishable from the single manipulations alone. (**C**) By quantal content, sustained PHP expression is abolished with chronic IP~3~ sequestration, acute 10 µM Dantrolene application, or both. (**D**) Representative electrophysiological traces for the conditions in (**A--C**). (**E**) Acute incubation 20 μM PhTox diminishes quantal size for all conditions shown. (**F**) EPSP amplitudes remain near genetic control levels for all conditions with PhTox application. There is a slight diminishment for the condition in which *UAS-IP~3~-sponge* is expressed and PhTox application is performed only after nerve dissection. (**G**) Full, rapid PHP induction or partial PHP induction by PhTox is present for all conditions shown. (**H**) Representative electrophysiological traces for the conditions in (**E--G**). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. Statistical comparisons for (**A--C**) and for wild type vs. wild type +PhTox are by Student's T-Test vs. unchallenged controls. Statistical comparisons across three data sets are by one-way ANOVA followed by Bonferroni post-hoc test across genotypes shown. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Scale bars for all traces are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.015Figure 7---source data 1.Raw electrophysiology data for [Figure 7](#fig7){ref-type="fig"}.Values as in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-39643-fig7){#fig7}

Axotomy does not block rapid PHP, even when IP~3~ signaling is impaired {#s2-8}
-----------------------------------------------------------------------

For larval NMJ electrophysiology, motor neurons are severed several minutes before recording ([@bib46]). Although standard practice, this procedure requires special attention in our study because store-operated calcium release mediates a variety of cellular responses after axotomy in rodent ([@bib83]) and nematode models ([@bib94]). For the rapid induction of PHP at the NMJ, PhTox is typically applied to intact synapses, prior to motor nerve severing and recording ([@bib28]). This allows for endogenous spontaneous activity to drive PhTox to bind to open channels prior to recording ([@bib28]). Nevertheless, rapid induction of PHP still works effectively when the motor nerves are severed prior to PhTox exposure ([@bib28]).

To test for a possible synergistic interaction between axotomy, IP~3~-directed signaling, and ER function during the acute induction phase of PHP, we applied PhTox to NMJs with intact motor nerves or with cut motor nerves (central nervous system (CNS) excised). We did this in a genetic background while expressing *UAS-IP~3~-sponge* construct pre- and postsynaptically. For controls, we treated the preparations identically and used GAL4 drivers alone for the genetic background. We found that rapid PHP induction still worked in the *UAS-IP~3~-sponge*-expressing background, regardless of whether the motor nerve was severed prior to PhTox application ([Figure 7E--G](#fig7){ref-type="fig"}). The evoked events were slightly diminished for the *UAS-IP~3~-sponge* expressing NMJs where the CNS was cut out of the preparation prior to PhTox application ([Figure 7F,H](#fig7){ref-type="fig"}). However, by quantal content measures, the rapid induction of PHP was not blocked by this dual treatment ([Figure 7G](#fig7){ref-type="fig"}).

Neuron and muscle IP~3~ signaling both contribute to long-term homeostatic potentiation {#s2-9}
---------------------------------------------------------------------------------------

Insofar, none of the genetic or pharmacological manipulations impairing PHP maintenance in this study have been tissue specific. In principle, all PHP-blocking manipulations described could operate either in neuronal or muscle substrates -- or upon both tissues. Our prior work showed that chronic *Plc21C* gene knockdown in the muscle alone is not sufficient to impair PHP ([@bib9]). That result suggested a neuronal component to this signaling system for PHP maintenance. Yet further tests are needed. We wished to understand whether a pre- or postsynaptic mechanism (or a dual-tissue mechanism) governs IP~3~-mediated Ca^2+^ store release signaling in order to support long-term maintenance of PHP.

We turned again to the *UAS-IP~3~-sponge* transgene because it can be expressed in a tissue-specific manner, and it conveyed a full block of PHP when dually expressed in the neuron and muscle ([Figure 2](#fig2){ref-type="fig"}). We expressed *UAS-IP~3~-sponge* in a GAL4 driver (neuron or muscle alone) or a driver +*GluRIIASP^SP16^* null genetic background. We then quantified PHP by NMJ electrophysiology, considering neuronal ([Figure 8A--C](#fig8){ref-type="fig"}) or muscle ([Figure 8D--F](#fig8){ref-type="fig"}) expression ([Supplementary file 7](#supp7){ref-type="supplementary-material"} for summary [Figure 8](#fig8){ref-type="fig"} data) ([Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"} for raw data). Surprisingly, we did not localize the full block of PHP maintenance to a single tissue. For expression in either tissue alone, there was still a small increase in QC in a *Gal4* \>\>*UAS-IP~3~-sponge + GluRIIASP^SP16^* genetic condition, compared to control *Gal4* \>\>*UAS-IP~3~-sponge* expression in an unchallenged background ([Figure 8C,F](#fig8){ref-type="fig"}). EPSP values were depressed when *UAS-IP~3~-sponge* was expressed neuronally in the *GluRIIA* null background ([Figure 8B,G](#fig8){ref-type="fig"}), consistent with an important neuronal component to PHP ([@bib9]). Combined with our prior data ([Figure 2](#fig2){ref-type="fig"}), we conclude that the maintenance of PHP can be fully erased by IP~3~ sequestration -- but only if this is done in a dual tissue manner.

![Combined pre-and postsynaptic IP~3~ signaling maintains PHP.\
*UAS-IP~3~-sponge* transgene expression in single tissue types impairs PHP maintenance, but does not block it. *IP~3~-sponge* either in neurons (**A--C**) or muscle (**D--F**). Wild-type and *GluRIIA* control data sets are replotted from [Figures 4](#fig4){ref-type="fig"}--[6](#fig6){ref-type="fig"} for visual comparison. (**A**) The *GluRIIA^SP16^* deletion mutation diminishes quantal size for all experimental conditions. (**B**) EPSP amplitudes are somewhat impaired versus non-*GluRIIA* control in all cases but most severely impaired when *GluRIIA* deletion is combined with presynaptic *IP~3~-sponge* expression. (**C**) By quantal content, sustained PHP is still present for all conditions shown. (**D**) The *GluRIIA^SP16^* deletion mutation diminishes quantal size for all experimental conditions. (**E**) EPSP amplitudes are somewhat impaired versus non-*GluRIIA* control. (**F**) By quantal content, sustained PHP is still present for all conditions shown. (**G**) Representative electrophysiological traces for conditions in (**A--F**). (**H**) *UAS-IP~3~-sponge* transgene expression does not impair calcium cooperativity of release. (**I**) Representative electrophysiological trances for conditions in (**H**). Violin plots used as in [Figure 1](#fig1){ref-type="fig"}. Statistical comparisons are by one-way ANOVA followed by Bonferroni post-hoc test across genotypes shown. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Scale bars in (**G**) apply to all traces in (**G**) and (**I**) and are *y* = 10 mV (1 mV), *x* = 20 ms (500 ms) for EPSPs (mEPSPs).\
10.7554/eLife.39643.017Figure 8---source data 1.Raw electrophysiology data for [Figure 8](#fig8){ref-type="fig"}.Values as in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.](elife-39643-fig8){#fig8}

Our data indicate that IP~3~ functions in a shared process with Ca^2+^ store release. Presynaptic neurotransmitter release at the NMJ and other synapses is highly sensitive to changes in intracellular Ca^2+^ concentration after influx through voltage-gated Ca~V~2 channels. Therefore, we checked if IP~3~ signaling and its effects on intracellular Ca^2+^ release might impinge upon the Ca^2+^ sensing machinery in the presynaptic cleft, which could potentially influence PHP. We conducted NMJ recordings over a range of low extracellular \[Ca^2+^\] and calculated the Ca^2+^ cooperativity of release for the dual-tissue expression *UAS-IP~3~-sponge* NMJs, as well as wild-type NMJs and GAL4 driver control NMJs. The Ca^2+^ cooperativity of release was steady between the three conditions ([Figure 8H,I](#fig8){ref-type="fig"}), indicating that sequestration of cellular IP~3~ at the NMJ does not directly alter the Ca^2+^-dependence of synaptic release at the presynaptic NMJ.

Discussion {#s3}
==========

In this study, we divided the acute induction and chronic maintenance stages of presynaptic homeostatic potentiation. Our data support two core findings. The first is that the short-term induction and long-term maintenance of PHP are separable by genetic and pharmacological manipulations. The second is that an IP~3~-mediated signaling system is specifically required for the maintenance of PHP ([Figure 9](#fig9){ref-type="fig"}).

![Model depicting PLCβ/IP3R/RyR signaling underling the maintenance of PHP in both muscle and neuron.\
At the *Drosophila* NMJ, PLCβ and effectors IP~3~R and RyR are required for the maintenance of HSP. Left: PLCβ signaling components depicted in both muscle and neuron at the *Drosophila* NMJ. We detected no apparent role for PLCβ, IP~3~R, or RyR in baseline neurotransmission. Right: Reduced postsynaptic glutamate receptor function -- either due to deletion of the *GluRIIA* gene or expression of *UAS-GluRIII\[RNAi\]* -- drives a chronic form of PHP that is maintained throughout life. A retrograde, muscle-to-nerve signal instructs the neuron to increase the number of neurotransmitter vesicles released (quantal content). Our data support a model in which long-term maintenance of PHP requires PLCβ and its effectors in both the presynaptic neuron and postsynaptic muscle, but these factors are dispensable for the rapid induction of PHP.](elife-39643-fig9){#fig9}

Acute versus chronic PHP expression {#s3-1}
-----------------------------------

For several years, one assumption has been that both the acute and chronic forms of PHP are executed in a similar way -- and possibly by shared mechanisms. The issue has been clouded by the fact that both PhTox and a *GluRIIA* deletion mutant -- the primary reagents utilized to induce PHP -- have the same molecular target, that is GluRIIA-containing glutamate receptors ([@bib28]; [@bib78]). The process of combining these acute and chronic forms of plasticity within a single genotypic background was cumbersome due to a lack of reagents available to conduct temporally separate targeting experiments.

Several groups ascertained insights into temporal requirements by targeting potential homeostatic signaling genes. The main finding has been that the majority of molecules identified are essential to both the acute and chronic forms of PHP ([@bib20]; [@bib30]). Neurons tightly control neurotransmitter release probability, and the core presynaptic machinery directly responsible for increasing quantal content is shared. These shared components include the Ca~V~2-type voltage-gated calcium channel or factors gating influx through the channel ([@bib28]; [@bib29]; [@bib63]; [@bib104]; [@bib105]; [@bib114]). They also include factors that regulate the size of the readily releasable pool (RRP) of presynaptic vesicles ([@bib40]; [@bib62]; [@bib61]; [@bib105]; [@bib107]; [@bib108]) or factors that control the baseline excitability or plasticity of the presynaptic motor neuron ([@bib2]; [@bib51]; [@bib69]; [@bib74]; [@bib114]) -- and neurotransmitter fusion events themselves ([@bib24]; [@bib23]; [@bib60]; [@bib70]). As a result, both the acute and chronic forms of PHP signaling cause increases in readily releasable pool (RRP) size and Ca~V~2-mediated calcium influx; and in turn, these presynaptic mechanisms underlie the increases in QC which constitute PHP ([@bib20]; [@bib63]; [@bib61]).

Here, we show that although the acute and chronic processes might overlap, they are functionally separable. The fact that they are separable is not necessarily surprising. This finding mirrors data for discrete molecules required for long-term PHP maintenance, such as Target of Rapamycin (Tor) ([@bib34]; [@bib48]; [@bib76]), the Rho-type guanine exchange factor Ephexin ([@bib29]), the transcription factor Gooseberry ([@bib56]), C-terminal Src Kinase ([@bib91]), innate immune signals molecules IMD, IKKβ, Relish ([@bib41]) and the kinesin adaptor Arl8 ([@bib35]; [@bib103]). Importantly, this list contains molecules implicated both in neuron and muscle. We have added PLCβ ([@bib9]) and its effectors IP~3~R and RyR to this list.

Recent studies have augmented the idea of overlapping signaling pathways and added a degree of specificity. Both acute and chronic forms of PHP begin as instructive retrograde signals after perturbations are detected in the muscle ([@bib42]; [@bib68]). These forms of PHP involve a decrease in phosphorylation of muscle CaMKII levels, and converge upon the same signaling components in the presynaptic neuron ([@bib34]; [@bib53]; [@bib65]). These studies suggest that Tor signaling converges on the same molecular targets as acute forms of PHP ([@bib34]). However, the precise roles for Tor and CaMKII in either form of PHP are as yet unknown.

Our data appear to contradict the idea of PHP pathway convergence ([@bib34]). Yet, our findings are not incompatible with this idea. Multiple lines of evidence indicate discrete signaling requirements for acute forms of PHP on both sides of the synapse. A convergence point is undefined. Accounting for the separation of acute and chronic forms of PHP -- as well as their discrete signaling requirements -- long-term maintenance of PHP might integrate multiple signals between the muscle and neuron over time. For future studies, it will be important to clearly define roles of signaling systems underlying PHP and how distinct signaling systems might be linked.

Unexpected findings about PHP stage separation {#s3-2}
----------------------------------------------

Our work presents unexpected findings. The first is that even in the face of a chronic impairment or block of homeostatic potentiation, the NMJ is nevertheless capable of a full rapid induction of PHP ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [7](#fig7){ref-type="fig"}). Given that most molecules required for PHP identified to date are needed for both phases, we did not expect significant functional separation between them. We expected a priori that a failure of the chronic maintenance of PHP would make core machinery unavailable for its acute induction. The second unexpected finding is how quickly the chronic maintenance of PHP can be nullified by pharmacology (10 min), resulting in a return to baseline neurotransmitter release probability after only minutes of drug exposure ([Figures 4](#fig4){ref-type="fig"}--[6](#fig6){ref-type="fig"}). We showed that homeostatic potentiation in *GluRIIA* mutant larvae or *GluRIII* knock-down larvae was abrogated by four different reagents previously known to block IP~3~R ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) or RyR ([Figure 6](#fig6){ref-type="fig"}). Those findings are reminiscent of prior work showing that acute blockade of DAG/ENaC channels with the drug benzamil abolishes PHP in both a *GluRIIA* mutant background, as well as in the presence of PhTox ([@bib114]). A difference between benzamil application and the pharmacological agents used in our study is that the drugs we employed only abolished PHP in a chronically challenged background.

Does PHP induction lead to maintenance? {#s3-3}
---------------------------------------

It is unclear how signaling systems that drive homeostatic plasticity transition from a state of induction to a state of maintenance. It is also not understood how interdependent short-term and long-term HSP implementation mechanisms are. A more complete understanding of the timing and perdurance of these properties could have important implications for neurological conditions where synapse stability is episodically lost ([@bib85]).

Our findings parallel recent data examining active zone protein intensities in the contexts of induction of PHP and maintenance of PHP at the NMJ. There are multiple results informative to our study. First, the expression of any form of PHP (acute or chronic) appears to correlate with an increased intensity of active zone protein levels, such as Ca~V~2/Cacophony ([@bib38]), UNC-13 ([@bib7]), and the Drosophila CAST/ELKS homolog Bruchpilot ([@bib7]; [@bib35]; [@bib38]). Unexpectedly, however, two of these studies also reported that the rapid induction of PHP does not require this protein increase in order to be functionally executed ([@bib7]; [@bib35]). These are conundrums for future work. How does rapid active zone remodeling happen in minutes on a mechanistic level? In the absence of such remodeling, how is PHP able to be induced rapidly? Moreover, is the observed short-term active zone remodeling the kernel for the longer-term changes to the active zone and release probability -- or is some other compensatory system triggered over long periods of developmental time (e.g., see multiple mechanisms described by [@bib36])?

Our findings add a new dimension to those puzzles with the data that IP~3~ signaling is continuously required to maintain PHP. If active zone remodeling truly is instructive for PHP maintenance, then it will be interesting to test what roles IP~3~ signaling and intracellular calcium release play in that process. Our screen did include a *UAS-RNAi* line against *unc-13* and an upstream GPCR-encoding gene *methuselah* ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Moreover, we previously published a study of PHP using a *UAS-cac\[RNAi\]* line ([@bib9]). Chronic PHP maintenance was intact for all of those manipulations. Those findings are not necessarily contradictory to the recent work from other groups. For instance, knockdown of an active zone protein by RNAi is not a null condition. As such, RNAi-mediated knockdown should leave residual wild-type protein around. In theory, that residual protein could be scaled with homeostatic need.

PLCβ- and IP~3~-directed Signaling is Required for PHP Maintenance {#s3-4}
------------------------------------------------------------------

Our data strongly suggest that intracellular calcium channel activation and store release fine tune neurotransmitter release that is implemented by PHP. The exact mechanism by which IP~3~R and RyR function to maintain PHP at the NMJ is unclear. It appears to be a shared process with IP~3~ ([Figure 7](#fig7){ref-type="fig"}). If these store-release channels are acting downstream of IP~3~ activity, then our data suggest that this would be a coordinated activity involving both the muscle and the neuron ([Figures 8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}) -- with loss of IP~3~ signaling in the neuron being more detrimental to evoked release ([Figure 8G](#fig8){ref-type="fig"}).

It remains unclear what signals are acting upstream. PLCβ is canonically activated by Gαq signaling. From our prior work, we garnered evidence that a *Drosophila* Gq protein plays a role in the long-term maintenance of HSP ([@bib9]). Logically, there may exist a G-protein-coupled receptor (GPCR) that functions upstream of PLCβ/IP~3~ signaling. Our screen did not positively identify such a GPCR. We did examine several genes encoding GPCRs, including *TkR86C*, *mAChR-A*, *GABA-B-R1*, *PK2-R2*, *methuselah*, *AdoR*, and *mGluR* ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). We also examined genes encoding Gβ subunits or putative scaffolding molecules, including *CG7611* (a WD40-repeat-encoding gene), *Gβ13F*, and *Gβ76C*, again with no positive screen hits ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

Our data are consistent with dual pre- and postsynaptic functions of IP~3~. This could mean dual pre- and postsynaptic roles for calcium store release -- through an undetermined combination of RyR and IP~3~R activities, again either pre- or postsynaptic. Both RyR and IP~3~R have been shown to be critical for specific aspects of neuroplasticity and neurotransmission ([@bib6]). Activities of both RyR and IP~3~R can activate molecules that drive plasticity, such as Calcineurin ([@bib102]) and CaMKII ([@bib88]). At rodent hippocampal synapses, electrophysiological measures like paired-pulse facilitation and frequency of spontaneous neurotransmitter release ([@bib27]) are modulated by RyR and/or IP~3~R function, as is facilitation of evoked neurotransmitter at the rat neocortex ([@bib59]). In addition to vesicle fusion apparatus, activity of presynaptic voltage-gated calcium channels is modulated by intracellular calcium ([@bib13]; [@bib52]). Our own work at the NMJ has shown that impairing factors needed for store-operated calcium release can mollify hyperexcitability phenotypes caused by gain-of-function Ca~V~2 amino-acid substitutions ([@bib10]).

Within the presynaptic neuron, IP~3~R and RyR could activate any number of calcium-dependent molecules to propagate homeostatic signaling. We tested some candidates in our screen ([Figure 2](#fig2){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}), but none of those tests blocked PHP. One possibility is that the reagents we utilized did not sufficiently diminish the function of target molecules enough to impact PHP in this directed screen. Detection of downstream effectors specific to muscle or neuron might also be hampered by the fact that attenuation of IP~3~ signaling in a single tissue is insufficient to abrogate PHP. Another possibility is that presynaptic store calcium efflux via IP~3~R and RyR may directly potentiate neurotransmitter release, either by potentiating basal calcium levels or synchronously with Ca~V~2-type voltage-gated calcium channels ([@bib28]; [@bib63]).

Both pre- and postsynaptic voltage-gated calcium channels are critical for the expression of several forms of homeostatic synaptic plasticity ([@bib31]). Much evidence supports the hypothesis that store-operated channels and voltage gated calcium channels interact to facilitate PHP. In various neuronal populations, both RyR and IP~3~R interact with L-type calcium channels physically and functionally to reciprocally impact the opening of the other channel ([@bib14]; [@bib50]; [@bib71]). In presynaptic boutons, RyR calcium release follows action potential firing ([@bib27]). Calcium imaging experiments show that both the acute expression and sustained maintenance of PHP requires an increase in presynaptic calcium following an action potential ([@bib63]). Because IP~3~Rs are activated by both free calcium and IP~3~, elevated IP~3~ levels in the case of chronically expressed PHP could allow IP~3~Rs and RyRs to open in a way that is time-locked with Ca~V~2-mediated calcium influx or in a way to facilitate the results of later Ca~V~2-mediated influx.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent\                                      Designation                                  Source or\                                                                                                   Identifiers                                                                               Additional\
  type (species)\                                                                            reference                                                                                                                                                                                              information
  or resource                                                                                                                                                                                                                                                                                       
  --------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Genetic Reagent (*Drosophila melanogaster*)   *GluRIII\[RNAi\]* or *UAS-GluRIII\[RNAi\]*   PMID: [25859184](http://www.ncbi.nlm.nih.gov/pubmed/25859184)                                                FlyBase ID:FlyBase_FBtp0110520                                                            *UAS-pWiz* transgene knocking down*GluRIII* gene function. This lab (CAF) is the source ([@bib9]).

  Genetic Reagent (*D. melanogaster*)           *Plc21C\[RNAi\]* or *UAS-Plc21C\[RNAi\]*     Vienna Drosophila Resource Center (GD11359); PMID: [17625558](http://www.ncbi.nlm.nih.gov/pubmed/17625558)   RRID:[FlyBase_FBst0456476](https://scicrunch.org/resolver/FlyBase_FBst0456476)            *UAS-RNAi* transgene

  Genetic\                                      *Plc21C\[RNAi\]* or *UAS-Plc21C\[RNAi\]*     Vienna Drosophila Resource Center (GD11359); PMID: [17625558](http://www.ncbi.nlm.nih.gov/pubmed/17625558)   RRID:[FlyBase_FBst0456477](https://scicrunch.org/resolver/FlyBase_FBst0456477)            *UAS-RNAi* transgene
  Reagent (*D. melanogaster*)                                                                                                                                                                                                                                                                       

  Genetic Reagent (*D. melanogaster*)           *UAS-IP~3~-sponge.m30*                       PMID: [16540404](http://www.ncbi.nlm.nih.gov/pubmed/16540404)                                                FlyBase ID:FlyBase_FBtp0068098                                                            also referred to as *UAS-IP~3~-sponge*

  Genetic Reagent (*D. melanogaster*)           *UAS-IP~3~-sponge.m49*                       PMID: [16540404](http://www.ncbi.nlm.nih.gov/pubmed/16540404)                                                FlyBase ID:FlyBase_FBtp0068099                                                            also referred to as *UAS-IP~3~-sponge*

  Genetic Reagent (*D. melanogaster*)           *GluRIIA^SP16^*                              PMID: [9427247](http://www.ncbi.nlm.nih.gov/pubmed/9427247)                                                  RRID:[BDSC_64202](https://scicrunch.org/resolver/BDSC_64202)                              deletion allele; also referred to as *GluRIIA*

  Genetic Reagent (*D. melanogaster*)           *w^1118^*                                    PMID: [6319027](http://www.ncbi.nlm.nih.gov/pubmed/6319027)                                                  RRID:[BDSC_3605](https://scicrunch.org/resolver/BDSC_3605)                                wild-type genetic background

  Genetic Reagent (*D. melanogaster*)           *elaV(C155)-Gal4*                            PMID: [7917288](http://www.ncbi.nlm.nih.gov/pubmed/7917288)                                                  RRID:[BDSC_458](https://scicrunch.org/resolver/BDSC_458)                                  also known as *C155-Gal4*

  Genetic Reagent (*D. melanogaster*)           *Sca-Gal4*                                   PMID: [8893021](http://www.ncbi.nlm.nih.gov/pubmed/8893021)                                                  FlyBase ID:FlyBase_FBtp0007534                                                            

  Genetic Reagent (*D. melanogaster*)           *BG57-Gal4*                                  PMID: [8893021](http://www.ncbi.nlm.nih.gov/pubmed/8893021)                                                  FlyBase ID:FlyBase_FBti0016293                                                            also known as *C57-Gal4*

  Chemical Compound, Drug                       Philanthotoxin-433; PhTox                    Sigma-Aldrich (MilliporeSigma); Santa Cruz Biotechnology                                                     CAS Number:(Sigma-Aldrich and Santa Cruz Biotechnology)\_276684-27-6                      product P207 discontinued by Sigma-Aldrich

  Chemical Compound, Drug                       Xestospongin C                               Abcam                                                                                                        CAS Number:Abcam_88903-69-9                                                               

  Chemical Compound, Drug                       2-APB                                        Tocris                                                                                                       CAS Number:Tocris_524-95-8                                                                

  Chemical Compound, Drug                       Ryanodine                                    Tocris                                                                                                       CAS Number:Tocris_15662-33-6                                                              

  Chemical Compound, Drug                       Dantrolene                                   Tocris                                                                                                       CAS Number:Tocris_14663-23-1                                                              

  Antibody                                      Monoclonal mouse anti-Synapsin               DSHB (3C11)                                                                                                  Cat\#: DSHB_3C11; RRID:[AB_2313867](https://scicrunch.org/resolver/AB_2313867)            (1:50)

  Antibody                                      Polyclonal rabbit anti-Dlg                   PMID: [8893021](http://www.ncbi.nlm.nih.gov/pubmed/8893021)                                                                                                                                            (1:15,000)

  Antibody                                      Polyclonal goat anti-mouse 488 (DyLight)     Jackson ImmunoResearch                                                                                       Cat \#:Jackson\_ 115-485-003; (no RRID)                                                   (1:1000) discontinued; substitute with Cat\# 115-485-068; RRID:[AB_2338804](https://scicrunch.org/resolver/AB_2338804)

  Antibody                                      Polyclonal goat anti-rabbit 549 (DyLight)    Jackson ImmunoResearch                                                                                       Cat\#:Jackson_111-505-003; RRID:[AB_2493180](https://scicrunch.org/resolver/AB_2493180)   (1:2000) discontinued; substitute with Cat\# 111-165-003; RRID:[AB_2338000](https://scicrunch.org/resolver/AB_2338000)

  Antibody                                      Polyclonal goat anti-HRP (Alexa-647)         Jackson ImmunoResearch                                                                                       Cat\#:Jackson_123-605-021; RRID:[AB_2338967](https://scicrunch.org/resolver/AB_2338967)   (1:250)

  Software, Algorithm                           pClamp                                       Molecular Devices                                                                                            RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)                              

  Software, Algorithm                           MiniAnalysis Program                         Synaptosoft                                                                                                  RRID:[SCR_002184](https://scicrunch.org/resolver/SCR_002184)                              

  Software, Algorithm                           GraphPad Prism                               GraphPad                                                                                                     RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Drosophila* husbandry {#s4-1}
----------------------

*Drosophila melanogaster* fruit flies were raised on Cornmeal, Molasses and Yeast Medium prepared according to the Bloomington Drosophila Stock Center (BDSC, Bloomington, IN) recipe. *Drosophila* husbandry was performed according to standard practices ([@bib39]). Larvae were raised at 25°C or 29°C in humidity controlled and light-controlled Percival DR-36VL incubators (Geneva Scientific).

*Drosophila* genetic lines {#s4-2}
--------------------------

*w^1118^* ([@bib43]) was used as a non-transgenic wild type stock. The deletion *GluRIIA* allele (*GluRIIA^SP16^*) was generated previously ([@bib78]). *UAS-IP~3~-sponge* lines (*UAS-IP~3~-sponge.m30* and *UAS-IP~3~-sponge.m49*) were provided by Drs. Masayuki Koganezawa and Daisuke Yamamoto ([@bib100]). The *UAS-GluRIII\[RNAi\]* line utilized to screen homeostatic candidate molecules was described previously ([@bib9]). GAL4 drivers simultaneously utilized for the *'Pre-+Post-Gal4*' conditions were *elaV(C155)-Gal4* ([@bib54]), *Sca-Gal4* ([@bib11]), and *BG57-Gal4* ([@bib11]).

In addition to the *UAS-IP~3~-sponge* lines, several *UAS-RNAi* or genetic mutant lines were obtained either from the BDSC or the Vienna Drosophila Resource Center (VDRC, Vienna, Austria). Those specific mutations and lines are detailed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Procedures for how the *UAS-RNAi* lines were generated have been published ([@bib25]; [@bib66]).

Electrophysiology and pharmacology {#s4-3}
----------------------------------

Wandering third instar larvae were collected and filleted for NMJ analysis. Control and experimental samples were collected in parallel, using identical conditions. Activity in abdominal muscle 6 from segments 2 and 3 was recorded in a modified HL3 saline (70 mM NaCl, 5 mM KCl, 5 mM HEPES, 10 mM NaHCO3, 115 mM sucrose, 0.5 mM CaCl~2~ (unless otherwise noted), 10 mM MgCl2, 4.2 mM trehalose, pH 7.2) (see [@bib92] for original parameters). Sharp electrode recordings of miniature excitatory postsynaptic potentials (mEPSPs) and excitatory postsynaptic potentials (EPSPs) were conducted as previously described ([@bib9]; [@bib91]; [@bib113]) and analyzed using MiniAnalysis (Synaptosoft) and pClamp10 (Molecular Devices) software, blind to genotype or treatment. Uncorrected quantal content (QC) was estimated per NMJ as average EPSP/average mEPSP and was also reported as corrected for non-linear summation as done previously ([@bib57]). For the correction factor formula ([@bib57]), we used a reversal potential of +10 mV (Supplemental Excel File).

Pharmacological agents were bath applied in recording saline at the final concentrations indicated in the text, figures, and tables. The agents included Philanthotoxin-433 (PhTox, Sigma-Aldrich and Santa Cruz Biotechnology), Xestospongin C (Abcam), 2-APB (Tocris, Bio-Techne Corporation), Ryanodine (Tocris), and Dantrolene (Tocris).

To render mEPSP and EPSP traces for figures, we pulled (x,y) coordinates from the Clampfit program (Molecular Devices) and imported those coordinates into GraphPad Prism (GraphPad) software. For all traces, we chose a recording that was at (or closest to) the calculated average. For mEPSPs, we picked a representative selection of minis. For EPSPs, the final trace that was rendered was an average of all the EPSP traces from that particular NMJ.

Immunostaining and analyses {#s4-4}
---------------------------

Immunostaining and image analyses of NMJ 6/7 in segments A2 and A3 were performed as previously described ([@bib91]; [@bib113]). Briefly, fileted larvae were fixed in Bouin's fixative for 4 min, washed, incubated in primary antibodies for 2 hr, washed, and incubated in secondary antibodies for an additional 2 hr. Bouton staining was performed to assess NMJ growth by using the following primary antibodies: mouse anti-Synapsin (anti-Syn; 3C11) 1:50 (Developmental Studies Hybridoma Bank, Iowa City, IA) and rabbit anti-Dlg 1:15,000 ([@bib11]). The following fluorophore conjugated secondary antibodies were also used (Jackson ImmunoResearch Laboratories): goat anti-mouse 488 1:1000 (DyLight) and goat anti--rabbit 549 1:2000 (DyLight). Goat anti-HRP 1:250 (Alexa-647) was utilized to stain neuronal membranes. Larval preparations were mounted in Vectashield (Vector Laboratories) and imaged at room temperature using Zen software on a Zeiss 880 Laser Scanning Microscope with an EC Plan-Neofluar 40X Oil DIC Objective (aperture 1.30) or an EC Plan-Apochromat 63X Oil DIC Objective (aperture 1.40; Zeiss). Experimental and control larval preps were imaged using identical acquisition settings and analyzed blind to genotype using the same procedure and thresholds. Images were prepared for publication in Adobe Photoshop using identical procedures for experimental and control images. Anti-Dlg bouton counts were completed in a blinded fashion to quantify synapse growth. For each anti-Dlg--positive bouton counted in muscle, it was verified that there was a corresponding cluster of anti-Syn staining in neurons.

Statistical analyses {#s4-5}
--------------------

For electrophysiological data, statistical significance was tested either by Student's T-Test if one experimental data set was being directly compared to a control data set, or by one-way ANOVA with a Bonferroni post-hoc test if multiple data sets were being compared. For bouton counting, significance was tested utilizing a Kruskal-Wallis ANOVA test followed by Dunn's post-hoc test. Specific p value ranges and tests are noted in the Figures and Figure Legends and Supplementary Files and shown in graphs as follows: \*p\<0.05, \*\*p\<0.01, and \*\*\*p\<0.001. All statistical analyses were conducted using GraphPad Prism Software. Most figure data are plotted as violin plots from GraphPad Prism; the violin plot shapes signify data distribution, *n* values are below those shapes, and horizontal lines signify the 0^th^, 25^th^, 50^th^, 75^th^, and 100^th^ percentiles of the data.
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10.7554/eLife.39643.019

###### Summary electrophysiological data for [Figure 1](#fig1){ref-type="fig"} (*Plc21C* RNAi experiments).

Genotypes and/or conditions are denoted. For GAL4 drivers, '*Pre +Post* Gal4' denotes a genetic combination of *elaV(C155)-Gal4/Y; Sca-Gal4/+; BG57-Gal4/+*. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.020

###### Summary electrophysiological data for [Figure 2](#fig2){ref-type="fig"} (screen and follow-up).

Genotypes and/or conditions are denoted. The data are split into two tables. The first table summarizes the screen data from [Figure 2A](#fig2){ref-type="fig"}. The second table summarizes the follow-up data examining the *UAS-IP~3~-sponge* reagent, including the homoeostatic block identified in the screen. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.021

###### Summary electrophysiological data for [Figure 4](#fig4){ref-type="fig"} (Xestospongin C application).

Genotypes and/or conditions are denoted. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.022

###### Summary electrophysiological data for [Figure 5](#fig5){ref-type="fig"} (2-APB application).

Genotypes and/or conditions are denoted. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.023

###### Summary electrophysiological data for [Figure 6](#fig6){ref-type="fig"} (Ryanodine and Dantrolene applications).

Genotypes and/or conditions are denoted. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.024

###### Summary electrophysiological data for [Figure 7](#fig7){ref-type="fig"} (manipulation interaction analyses).

Genotypes and/or conditions are denoted. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.025

###### Summary electrophysiological data for [Figure 8](#fig8){ref-type="fig"} (tissue specificity analyses).

Genotypes and/or conditions are denoted. Average values ± SEM are presented for each electrophysiological parameter, with *n* = number of NMJs recorded. Values include miniature excitatory postsynaptic potential (mEPSP) amplitude, mEPSP frequency (Freq), excitatory postsynaptic potential (EPSP) amplitude, quantal content (QC), and QC corrected for non-linear summation (NLS). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. unchallenged control.

10.7554/eLife.39643.026

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files. Summary data for electrophysiology are included in the Supplementary Tables. Raw data for all figures are included in the Raw Data Workbook Excel file.
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Decision letter

VijayRaghavan

K

Reviewing Editor

National Centre for Biological Sciences, Tata Institute of Fundamental Research

India

In the interests of transparency, eLife includes the editorial decision letter, peer reviews, and accompanying author responses.

\[**Editorial note:** This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor\'s assessment is that all the issues have been addressed.\]

Thank you for submitting your article \"Maintenance of homeostatic plasticity at the *Drosophila* neuromuscular synapse requires continuous IP~3~-directed signaling\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by K VijayRaghavan as the Reviewing Editor and Senior Editor. The reviewers have opted to remain anonymous.

The Reviewing Editor has highlighted the concerns that require revision and/or responses, and we have included the separate reviews below for your consideration. If you have any questions, please do not hesitate to contact us.

Summary (From Reviewer \#1):

Synaptic homeostasis comprises a number of processes that help to maintain the strength of synaptic transmission at an optimal level through a variety of conditions. One accessible model for this is the *Drosophila* NMJ, at which a reduction in postsynaptic receptor capacity (typically measured as mEPSPs) leads to a compensatory increase in the number of synaptic vesicles released (QC, quantal content), so as to maintain overall synaptic strength. Both acute (pharmacologically induced) and chronic (genetically induced) homeostatic responses to lowered postsynaptic receptor capacity can be observed at the NMJ, but the extent to which they share similar mechanisms has not been extensively investigated.

James et al. present strong evidence that the two responses can be separated -- most strikingly that in some circumstances that impair the response to chronic receptor blockage, the response to acute blockage remains intact. They also present evidence for a partial mechanism, using both genetics and pharmacology to implicate release from both presynaptic and postsynaptic ER calcium stores in the mechanism, and also provide evidence that both pre- and post-synaptic mechanisms are involved.

The main strength of the work is that it is potentially a valuable contribution to dissecting the two responses (acute and chronic), and their molecular mechanisms; it should, therefore, be of wide interest, and also suggests directions for future mechanistic work on the area. My main criticism is that the authors\' conclusions depend critically on their quantitative and statistical analyses, and these are not currently explicit or complete enough for me to give my wholehearted support to the paper. These shortcomings would, therefore, need to be addressed -- I\'ve elaborated in more depth in the section below on data and statistics.

Separate reviews (please respond to each point):

*Reviewer \#1:*

Introductory Paragraph of Reviewer 1 is the summary above.

Minor Comments:

Subsection "Pharmacology targeting Ryanodine Receptors uncouples the induction and maintenance of PHP" and Discussion. The authors argue that IP~3~R and RyR function in a common pathway. But if blockage of either abolishes chronic homeostasis, is it not equally plausible that they function independently, but that both are necessary for homeostasis?

Subsection "PLCb- and IP~3~-directed Signaling is Required for PHP Maintenance": The downstream consequences of blocking RyR and IP~3~R signaling are discussed at length here, but hardly anything about the possible upstream events. And is it plausible that one of these could be acting (more) presynaptically and the other (more) postsynaptically?

Figure 6A. One of the important comparisons should be *GluRIIA* driver control with *GluRIIA* IP~3~-sponge? This comparison is shown for only 3 of the 4 graphs in A and B, but not for the left graph in A. Presumably it should also be shown in A? And why is there a comparison here of driver control with IP~3~ sponge, but not in the other graphs?

Introduction, sentence four: has \> have

Introduction paragraph four: previously identified Plc21 -- as what?

Introduction paragraph five: *Drosophila* in italics (maybe elsewhere too, I just noticed it here)

Subsection "Pharmacology targeting IP~3~ receptors uncouples the induction and maintenance of PHP": throughout the soma (including synapses) -- soma does not include synapses

Additional data files and statistical comments (important):

1\) Instead of showing graphs with mean [+]{.ul} SEM superimposed on a bar, graphs should show mean [+]{.ul} SEM, or box and whiskers (median and interquartile range, with 5/95 or 10/90 percentiles) for non-parametric distributions, superimposed on all datapoints. Number of datapoints should be stated for each mean [+]{.ul} SEM or box/whiskers.

2\) Comparisons would be easier to visualize if the same quantities were always graphed together, e.g. all mEPSPs together across genotypes or treatments, or all QCs together, as in Figure 6 -- instead of grouping genotypes or treatments, as in other figures.

3\) A corollary of points 1 and 2 is that the distribution of control datapoints should also be shown for all graphs, rather than just showing the non-control readings expressed as numbers normalized to controls.

4\) A corollary or points 1, 2 and 3 is that all readings in graphs should be expressed as raw units, e.g. mV, not normalized to 100. This is necessary for the reader to assess how the authors\' values compare with those of other workers, and even across the paper.

5\) The authors also leave a lot up to the faith of the reader by presenting \"typical\" plots of EPSPs and mini-EPSPs. For a paper where so much hangs by the quantitative comparisons, I\'d rather see plots of mean EPSPs (although this may not be possible for mEPSPs).

6\) When the authors show graphs of mEPSPs and QC, they should also show an equivalent graph for EPSPs across genotypes or treatments. The authors\' conclusions depend critically on their estimates of QC, and because of the non-linear relationship of QC with increasing EPSP magnitude, the correction required makes QC estimate less accurate for large EPSPs than for small ones. This intrinsic inaccuracy also a reason why the authors must do better at showing their raw data and analyses. The ideal solution would be to use 2-electrode voltage clamping to measure mEPSCs and EPSCs, so that no correction is required to estimate QC -- although the authors\' approach might still be enough if they improve the rigor used to show and explain their measurements and analyses.

7\) Since the authors\' quantitative analyses are so critical to their conclusions, they should also deposit all their supporting raw datapoints and analyses (not just summarized parameters as in current Supplementary files), either in supplementary info, or with a permanent DOI in a public data repository, linked to the paper. Datapoints should be deposited in a file format that allows any reader to analyze them, e.g. csv/tsv, Excel, Graphpad or a common stats package. GraphPad Prism files are convenient since they also show analyses, but since not all readers may have the relevant software, datapoints should also be provided in a widely accessible format like tsv/csv/Excel.

*Reviewer \#2:*

The study by James el al follows up on their previous identification of PLCβ as a key enzyme for maintenance of PHP. Here they dissect the signaling downstream PLCβ and show that IP~3~ and Ryanodine receptor (RyR) are part of the same signaling pathway required to maintain PHP. Interestingly, synapses with impairements in PLCβ, IP~3~ or RyR signaling respond to acute pharmacological challenges (such as PhTox) albeit thay cannot sustain expression of PHP. The authors combine genetics and pharmacological manipulations to document the separation of induction vs. maintenance processes in presynaptic homeostatic plasticity.

Strengths:

1\) Molecular pinning of the short-term induction and long-term maintenance processes during PHP. The authors have already contributed to the conceptual separation of the two processes as well as the basis for acute and chronic synaptic homeostasis. Here they take these studies further and describe a signaling pathway and pharmacological tools that differentiate between PHP induction and maintenance.

2\) Clever use of genetics and pharmacological manipulations to challenge the system and isolate different responses.

3\) The authors show that release of calcium from intracellular stores is required for the maintenance of PHP; this is separate from the presynaptic neurotransmitter release, which is highly sensitive to Ca^2+^ influx through voltage-gated Cav2 channels.

4\) They report that PHP adjusts neurotransmission release independent of the mechanisms that set baseline levels.

5\) Well written manuscript, with strong arguments and clearly described contributions to the field.

Weaknesses:

1\) The authors find that IP~3~ signaling in both neuron and muscle contribute to the long-term homeostatic potentiation, but the underlyining pre- or postsynaptic mechanisms remain unknown. At the least, the athors should measure the RRP size. Ideally, Ca^2+^ influx should also be determined.

2\) As described in the text, once PLCβ is activated by Gαq, it cleaves the PIP2 into DAG and IP~3~. In here, the authors only address the role of IP~3~-directed signaling. What about DAG? In *C. elegans*, DAG is thought to recruit UNC-13 at release sites, potentiating synaptic transmission (McMullan et al., Genes Dev. 2006).

3\) Previous studies (including by these authors) have demonstrated that motoneuron activity is not required for the rapid induction of synaptic homeostasis. Severing the axon does not disrupt the PHP induction; however, the ER and the RyR activity should be greatly altered. Is the induction of PHP in severed axons less efficient in the absence of PLCβ, IP~3~ or RyR? How do the authors reconcile their observations?

4\) Xestospongin-C appears to inhibit voltage-dependent Ca^2+^ and K^+^ currents at a concentration range similar to that at which it inhibits the IP~3~ receptor in intact smooth muscle in rodents (Ozaki et al., 2002). Thus, Xestospongin-C is a selective blocker of the IP~3~ receptor in permeabilized cells but is likely less efficient in cells with intact plasma membrane such as *Drosophila* NMJ. Are there any inhibitory effects of Xestospongin-C on pre- and/or postsynaptic voltage-dependent Ca^2+^ and K^+^ currents at larval NMJ?

5\) 2-APB impairs IP~3~R but also other targets such as TRP channels. A TRPV channel, Inactive (Iav), maintains presynaptic resting Ca^2+^ concentration by promoting Ca^2+^ release from the ER in *Drosophila* motor neurons, and is required for both synapse development and neurotransmission (Wong et al., 2014). Did the authors measure any effects of 2-APB on Inactive (or other *Drosophila* TRP channels)? How could they rule out that 2-APB influences the TRP channels-mediated basal neurotransmission and/or synaptic homeostasis?

Minor Comments:

Figure 3. The number of boutons should be reported per muscle area.

10.7554/eLife.39643.029

Author response

> Separate reviews (please respond to each point):

Reviewer \#1:

> Minor Comments:
>
> Subsection "Pharmacology targeting Ryanodine Receptors uncouples the induction and maintenance of PHP" and Discussion. The authors argue that IP~3~R and RyR function in a common pathway. But if blockage of either abolishes chronic homeostasis, is it not equally plausible that they function independently, but that both are necessary for homeostasis?

The reviewer is correct; this is one potential interpretation of the data. There is not necessarily a direct linear link between IP~3~, IP~3~R, and RyR. We revised our text to include this possibility. We also removed a pathway cartoon model that was included in the original submission. In terms of defining a "pathway," we explain our thinking in more detail here.

By classical analysis, phenotypic non-additivity of two or more similar manipulations is consistent with a common pathway -- as long as at least one manipulation is a functional null. Phenotypic additivity that is more severe than the single manipulations is consistent with parallel pathways.

For our study, the output is presynaptic homeostatic potentiation (PHP) -- i.e., when the NMJ is challenged, how much the quantal content is potentiated vs. baseline. The raw measures are spontaneous and evoked depolarization. We found that the UAS- IP~3~-sponge expression and 10 µM dantrolene manipulations alone each abrogate the long-term maintenance of PHP. Each manipulation alone is "null" for PHP maintenance. With both manipulations together, there is no further decrease in the level of evoked synaptic neurotransmission versus either manipulation alone. These data suggest that the two manipulations are acting upon the same process and not blunting neurotransmission through divergent processes that are independent of PHP maintenance. This is how we made our "pathway" interpretation.

The reviewer's point is well taken. Whether that specific form of PHP regulation is through a direct linear pathway or through a convergent pathway is not determined. We revised the text in recognition of this point.

> Subsection "PLCb- and IP~3~-directed Signaling is Required for PHP Maintenance": The downstream consequences of blocking RyR and IP~3~R signaling are discussed at length here, but hardly anything about the possible upstream events. And is it plausible that one of these could be acting (more) presynaptically and the other (more) postsynaptically?

This is a good point. Possible upstream signals include those that activate PLCb, potentially through Gq-coupled GPCRs. In our prior publication (Brusich et al., 2015), we showed that partial loss of Gq function partially impaired homeostatic plasticity. In our revised Discussion section, we include information about potential upstream signals.

The reviewer is correct regarding tissue type. The signaling roles for RyR and IP~3~R could be in separate tissues (or in both tissues). Our data are consistent with dual pre- and postsynaptic functions for IP~3~. Our texts includes all of the possibilities that go along with that data.

> Figure 6A. One of the important comparisons should be GluRIIA driver control with GluRIIA IP~3~-sponge? This comparison is shown for only 3 of the 4 graphs in A and B, but not for the left graph in A. Presumably it should also be shown in A? And why is there a comparison here of driver control with IP~3~ sponge, but not in the other graphs?

We thank the reviewer for pointing this out. Those data in the original submission Figure 6 are now in Revision Figure 8. We display parallel comparisons for all panels in Figures 8A-F.

> Introduction, sentence four: has \> have

Correct, thank you.

> Introduction paragraph four: previously identified Plc21 -- as what?

Thank you. We previously identified Plc21C as a factor needed to implement PHP. We edited the text.

> Introduction paragraph five: Drosophila in italics (maybe elsewhere too, I just noticed it here)

We have italicized all instances of *Drosophila* and *Drosophila melanogaster* in the revision. The exceptions are instances of *Drosophila* that are unitalicized in citation titles and also the unitalicized names of the two organizations from which we acquired many of the fly lines we used (Bloomington *Drosophila* Stock Center and Vienna *Drosophila* Resource Center). For the original submission we had only italicized the instances that included both genus and species names.

> Subsection "Pharmacology targeting IP~3~ receptors uncouples the induction and maintenance of PHP": throughout the soma (including synapses) -- soma does not include synapses

Correct, thank you. The sentence should read that the ER is known to localize throughout neurons (including synaptic terminals).

> Additional data files and statistical comments (important):
>
> 1\) Instead of showing graphs with mean [+]{.ul} SEM superimposed on a bar, graphs should show mean [+]{.ul} SEM, or box and whiskers (median and interquartile range, with 5/95 or 10/90 percentiles) for non-parametric distributions, superimposed on all datapoints. Number of datapoints should be stated for each mean [+]{.ul} SEM or box/whiskers.

We revised every data figure in response to this comment. We agree that there are more informative ways to visualize data than bar graphs +/- SEM.

We tried plotting box-and-whisker plots superimposed on all data points. When we plotted individual points, it added a visual difficulty -- namely, the points (no matter how small we rendered them) frequently obscured important information (e.g. where the 25^th^, 50^th^, and 75^th^ percentiles were). As an alternative, we used violin plots for the revision. The violin plots are composed of lines at the 0^th^, 25^th^, 50^th^, 75^th^, and 100^th^ percentiles. They contain all information that would have been in a box-and-whisker plots. Moreover, the violin shape demonstrates the data distribution, which serves a similar purpose as plotting all points. *n* values are beneath the violins.

In the interest of transparency (and as suggested by the reviewer in a subsequent comment below), we also compiled an Excel sheet reporting raw data for all individual data points for electrophysiological recordings or synapse growth measurements. By including the Excel data sheet with the manuscript, we hope that this serves a similar purpose as would be served by plotting all of those data points. The only figure for which we do not do this is revision Figure 2A. Figure 2A summarizes the screen data. Still, for the screen we report the summary data in table form.

> 2\) Comparisons would be easier to visualize if the same quantities were always graphed together, e.g. all mEPSPs together across genotypes or treatments, or all QCs together, as in Figure 6 -- instead of grouping genotypes or treatments, as in other figures.

This is a helpful point. For the revision, we graphed the same measures together across genotypes and treatments.

> 3\) A corollary of points 1 and 2 is that the distribution of control datapoints should also be shown for all graphs, rather than just showing the non-control readings expressed as numbers normalized to controls.

We agree that this is a better way to compare data sets. For the revision, we show the control data sets as violin plots. We also added all individual control data points to the Excel document.

> 4\) A corollary or points 1, 2 and 3 is that all readings in graphs should be expressed as raw units, e.g. mV, not normalized to 100. This is necessary for the reader to assess how the authors\' values compare with those of other workers, and even across the paper.

For the revision, we plotted all of the readings as raw units, rather than as relative percentages. The exception is Figure 2A, where a summary of the relative increase in quantal content was needed to assess whether or not a screen candidate expressed PHP.

> 5\) The authors also leave a lot up to the faith of the reader by presenting \"typical\" plots of EPSPs and mini-EPSPs. For a paper where so much hangs by the quantitative comparisons, I\'d rather see plots of mean EPSPs (although this may not be possible for mEPSPs).

We hope that by showing the raw data measures in the revision that we are not leaving anything quantitative up to subjective judgement, either by averages or by statistics.

We thank the reviewer for pointing out a potential point of confusion with regard to electrophysiological traces. Our strategy for picking a representative EPSP trace for a dataset condition has been to analyze NMJs individually and then to calculate averages across all NMJs in the dataset. To pull a trace from a specific recording, we pick a recording that is at (or nearly at) the calculated average. In the case of EPSPs, the final trace that is rendered is an average of all the EPSP recordings from that particular NMJ. We have clarified these methods for the revision.

If we are interpreting the reviewer's comment correctly, it seems that the preference would be to have our software render a single EPSP trace that represents the entire dataset, instead of just one NMJ. This is possible. For a typical dataset this might be *n* = 15 muscles x 30 EPSPs analyzed per muscle = 450 EPSPs analyzed per genotype. Yet that method would not generate a visual trace that is appreciably different in depolarization than the one that we are already rendering for the "typical" NMJ from the dataset. Moreover, it would not represent any real NMJ recording, but it would be rendering of many recordings.

The reviewer is correct about rendering mEPSPs; an "average of averages" sort of rendering across all muscles is not practical for that measure.

> 6\) When the authors show graphs of mEPSPs and QC, they should also show an equivalent graph for EPSPs across genotypes or treatments. The authors\' conclusions depend critically on their estimates of QC, and because of the non-linear relationship of QC with increasing EPSP magnitude, the correction required makes QC estimate less accurate for large EPSPs than for small ones. This intrinsic inaccuracy also a reason why the authors must do better at showing their raw data and analyses. The ideal solution would be to use 2-electrode voltage clamping to measure mEPSCs and EPSCs, so that no correction is required to estimate QC -- although the authors\' approach might still be enough if they improve the rigor used to show and explain their measurements and analyses.

There are multiple considerations in choosing two-electrode voltage clamp (TEVC) vs. sharp electrode bridge mode recordings of synaptic voltages for this prep. The reviewer is correct -- TEVC yields real calculations of QC after measuring currents, while recording in bridge mode yields estimates of QC after measuring synaptic voltages. TEVC also offers information about membrane current kinetics. On the other hand, noise levels of a TEVC recording are far greater than in bridge mode and can lead to consequential inaccuracies in analyzing the mEPSC quanta and the calculated QC. This would be especially true for our recordings in which were concurrently knocking down *GluRIII* gene function and applying PhTox-433.

Our compromise has been to record mEPSPs and EPSPs in an external \[Ca^2+^\] that is low. This serves to diminish possible effects of non-linear summation (NLS), and it is a common practice in the field. We do take NLS into account by calculating QC, both without a correction and with a correction. This is also common practice if synaptic voltages are recorded. We source the NLS correction method (Martin, 1955) in the revised Materials and methods. The full data (including the uncorrected QCs and corrected QCs) are in the new Excel spreadsheet we have included with the revision.

> 7\) Since the authors\' quantitative analyses are so critical to their conclusions, they should also deposit all their supporting raw datapoints and analyses (not just summarized parameters as in current Supplementary files), either in supplementary info, or with a permanent DOI in a public data repository, linked to the paper. Datapoints should be deposited in a file format that allows any reader to analyze them, e.g. csv/tsv, Excel, Graphpad or a common stats package. GraphPad Prism files are convenient since they also show analyses, but since not all readers may have the relevant software, datapoints should also be provided in a widely accessible format like tsv/csv/Excel.

This is a good suggestion. We are providing an Excel data sheet for the final version of the paper. This file will be downloadable by readers who would like to study our raw data.

Reviewer \#2:

> The study by James el al follows up on their previous identification of PLCβ as a key enzyme for maintenance of PHP. Here they dissect the signaling downstream PLCβ and show that IP~3~ and Ryanodine receptor (RyR) are part of the same signaling pathway required to maintain PHP. Interestingly, synapses with impairements in PLCβ, IP~3~ or RyR signaling respond to acute pharmacological challenges (such as PhTox) albeit thay cannot sustain expression of PHP. The authors combine genetics and pharmacological manipulations to document the separation of induction vs. maintenance processes in presynaptic homeostatic plasticity.
>
> Strengths:
>
> 1\) Molecular pinning of the short-term induction and long-term maintenance processes during PHP. The authors have already contributed to the conceptual separation of the two processes as well as the basis for acute and chronic synaptic homeostasis. Here they take these studies further and describe a signaling pathway and pharmacological tools that differentiate between PHP induction and maintenance.
>
> 2\) Clever use of genetics and pharmacological manipulations to challenge the system and isolate different responses.
>
> 3\) The authors show that release of calcium from intracellular stores is required for the maintenance of PHP; this is separate from the presynaptic neurotransmitter release, which is highly sensitive to Ca^2+^ influx through voltage-gated Cav2 channels.
>
> 4\) They report that PHP adjusts neurotransmission release independent of the mechanisms that set baseline levels.
>
> 5\) Well written manuscript, with strong arguments and clearly described contributions to the field.

We thank the reviewer for this overall positive assessment of the manuscript.

> Weaknesses:
>
> 1\) The authors find that IP~3~ signaling in both neuron and muscle contribute to the long-term homeostatic potentiation, but the underlyining pre- or postsynaptic mechanisms remain unknown. At the least, the athors should measure the RRP size. Ideally, Ca^2+^ influx should also be determined.

The reviewer is correct. There are tissue-specific aspects of the mechanism that we do not yet know. The comment points to two related presynaptic mechanisms (RRP size, Ca^2+^ influx). Prior studies have documented increases in presynaptic Ca^2+^ transients and increases in RRP size after a homeostatic challenge, like PhTox application (induction) or *GluRIIA* gene mutation (maintenance). Those measures correlate with whether or not PHP induction and maintenance are successful.

There are confounding issues for this particular study. Given these confounds, we believe it is appropriate to leave this mechanistic analysis for future studies. First, as pointed out by the reviewer, multiple mechanisms are likely implemented given the dual pre- and postsynaptic requirement for IP~3~ signaling. Second, to measure Ca^2+^ transients at the NMJ, one usually uses Ca^2+^ indicators that flood the terminal. Given the timescale of evoked release, such indicators would not easily distinguish between influx through Ca~V~2-type channels vs. efflux from stores like the endoplasmic reticulum (ER). It is probable that sequestration of IP~3~ and pharmacological impairment of IP~3~Rs or RyRs affect the latter. Finally, it is not trivial to separate increases in terminal Ca^2+^ from increases in RRP size. By definition, greater influx of extracellular Ca^2+^ will recruit more vesicles to be released.

> 2\) As described in the text, once PLCβ is activated by Gαq, it cleaves the PIP2 into DAG and IP~3~. In here, the authors only address the role of IP~3~-directed signaling. What about DAG? In C. elegans, DAG is thought to recruit UNC-13 at release sites, potentiating synaptic transmission (McMullan et al., Genes Dev. 2006).

When we designed our screen (Figure 2 and Supplementary file 2), we did consider the possible effects of diacyl glycerol (DAG). We included a *UAS-RNAi* line against *unc-13* in our screen, and we also included a *UAS-PKCi* (inhibitory) construct, since DAG is known to activate PKC and affect Ca~V~2 channel activity. In neither case did we observe a block of PHP maintenance. Those data are summarized in Supplementary file 2.

Negative data from a screen do not rule out a molecule or a process. Thus, based on our screening data alone, we agree with the reviewer that the DAG branch of the pathway has not been thoroughly examined. For the remainder of the study, we focused on the IP~3~ branch of the pathway because of our screen results.

Interestingly, new studies that touch upon this issue have been published since our original submission (Goel et al., 2019; Böhme et al., 2019; and Gratz et al., 2019). These new studies indicate that active zone proteins like UNC-13A, Cacophony (Cac), and Bruchpilot (Brp) scale with release, by immunostaining or by examining endogenously tagged Cac. We cite these new studies in our revision.

Those published results do not necessarily mean that one would expect *unc-13\[RNAi\]* or *cac\[RNAi\]* to yield a positive hit in a homeostasis screen like ours. That is because knockdown of gene function by RNAi is a not a null condition. It should still leave residual wild-type UNC-13A protein around. That residual wild-type UNC-13A could theoretically be scaled with homeostatic need. We previously addressed with issue with *cac*. Knock down by RNAi of Ca~V~2/*cacophony* does not prevent PHP maintenance (Brusich et al. *Frontiers in Cell. Neuro*), even though Cac protein levels scale with PHP (Goel et al., 2019; Böhme et al., 2019 and Gratz et al., 2019).

> 3\) Previous studies (including by these authors) have demonstrated that motoneuron activity is not required for the rapid induction of synaptic homeostasis. Severing the axon does not disrupt the PHP induction; however, the ER and the RyR activity should be greatly altered. Is the induction of PHP in severed axons less efficient in the absence of PLCβ, IP~3~ or RyR? How do the authors reconcile their observations?

The reviewer's experiment is interesting and not previously tested to our knowledge. To test for a possible synergistic interaction between severing axons, IP~3~-directed signaling, and ER function during the acute induction phase of PHP, we applied PhTox to NMJs with intact motor nerves or with cut motor nerves; moreover, we did this in a genetic background while expressing the *UASIP~3~-sponge* construct pre- and postsynaptically (drivers alone for control). The result is that PHP induction still works in the *UAS-IP~3~-sponge*-expressing background, regardless of whether or not the motor nerve is severed during drug application (Figure 7).

This result is consistent with the prior work. Motor nerve severing does not impair PHP induction by PhTox (Frank et al., 2006); IP~3~ sequestration does not prevent PHP induction by PhTox with an intact preparation (present study, revision Figures 2, 7); and motor nerve severing plus IP~3~ sequestration does not prevent PHP induction with a severed nerve preparation (present study, revision Figure 7). Combined motor nerve severing and IP~3~ sequestration may make the process a little less efficient (Figure 7), but PHP is still present.

> 4\) Xestospongin-C appears to inhibit voltage-dependent Ca^2+^ and K^+^ currents at a concentration range similar to that at which it inhibits the IP~3~ receptor in intact smooth muscle in rodents (Ozaki et al., 2002). Thus, Xestospongin-C is a selective blocker of the IP~3~ receptor in permeabilized cells but is likely less efficient in cells with intact plasma membrane such as Drosophila NMJ. Are there any inhibitory effects of Xestospongin-C on pre- and/or postsynaptic voltage-dependent Ca^2+^ and K^+^ currents at larval NMJ?

We thank the reviewer for pointing this out. We added this additional reference to our text in order to report known effects of Xestospongin C.

For the *Drosophila* NMJ, we do not have direct data addressing this particular question. However, we do know that impairment of voltage-dependent Ca^2+^ and K^+^ currents would likely have profound effects on baseline neurotransmission. Our data argue against the idea: Xestospongin C application does not have appreciable effects on baseline presynaptic release (e.g. revision Figure

4).

In principle, Xestospongin C could be affecting presynaptic or postsynaptic parameters, independent of the IP~3~ receptors. There potential issues with specificity or selectivity with any pharmacological reagent. This is why we tested multiple reagents, in addition to compiling genetic lines of evidence.

> 5\) 2-APB impairs IP~3~R but also other targets such as TRP channels. A TRPV channel, Inactive (Iav), maintains presynaptic resting Ca^2+^ concentration by promoting Ca^2+^ release from the ER in Drosophila motor neurons, and is required for both synapse development and neurotransmission (Wong et al., 2014). Did the authors measure any effects of 2-APB on Inactive (or other Drosophila TRP channels)? How could they rule out that 2-APB influences the TRP channels-mediated basal neurotransmission and/or synaptic homeostasis?

The reviewer is correct. We had similar thoughts -- a *priori*, we thought that Inactive could be a potential signaling component, so we included it in the screen (see Supplemental file). The screen did not produce data suggesting that Inactive is required for PHP maintenance. With the caveat that a negative screen result would not necessarily rule out a factor's involvement, our data do not support the idea that 2-APB is exerting its effects on PHP through Inactive. For completeness, we cite the reference mentioned by the reviewer in our revision.

> Minor Comments:
>
> Figure 3. The number of boutons should be reported per muscle area.

We include this measurement for the revision Figure 3.
